SCHEMBL419394

SCHEMBL419394

O=C(Nc1ccc(C23CC4CC(CC(C4)C2)C3)cc1)C(=O)Nc1ccc(Cl)cc1C(=O)O.[NaH]

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 4/20 0.72
NPC1 O15118 1/20 0.50
EPHX2 P34913 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 2/20 0.46
HIF1A Q16665 2/20 0.45
EPAS1 Q99814 1/20 0.45
P2RX7 Q99572 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
GRIK1 P39086 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
AKR1C4 P17516 1/20 0.40
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
AKR1C1 Q04828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL419525 0.99 SERPINE1 (0.74) SERPINE1NPC1EPHX2KDM4EHSD17B10
SCHEMBL419393 0.88 SERPINE1 (0.59) SERPINE1NPC1EPHX2HIF1AEPAS1
SCHEMBL418483 0.87 SERPINE1 (0.58) SERPINE1NPC1EPHX2HIF1AEPAS1
SCHEMBL420035 0.84 SERPINE1 (1.00) SERPINE1KDM4EHSD17B10CA1CA2
SCHEMBL418618 0.80 SERPINE1 (0.69) SERPINE1NPC1EPHX2KDM4EHSD17B10
SCHEMBL29838666 0.80 SERPINE1 (0.69) SERPINE1NPC1KDM4EHSD17B10LMNA
SCHEMBL416752 0.79 HIF1A (0.74) SERPINE1HIF1AEPAS1
SCHEMBL4650462 0.78 SERPINE1 (0.66) SERPINE1
SCHEMBL416528 0.77 SERPINE1 (0.65) SERPINE1KDM4EHIF1AEPAS1LMNA
SCHEMBL417709 0.77 SERPINE1 (1.00) SERPINE1CA1CA2CA9AKR1C4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
EP-2990057-B1 PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT RENASCIENCE CO LTD (JP) 2019-03-20 EP disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885NPC1 893/4885EPHX2 2172/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885NPC1 893/4885EPHX2 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.